Instead the EPA is pushing the use of NOx "adsorption" systems, which act like giant sponges, essentially trapping the NOx chemically in the exhaust system.
Oral active versions of the narrower differentiation profiles mentioned above (agonists, dual pharmacology, conjugates) could be interesting, but gastric stability and adsorption may preclude those from working optimally and may conflate the risk profile.